



ASX ANNOUNCEMENT

24 October 2023

Appendix 3Y – Late Lodgement Notice

Please find attached the Appendix 3Y “Change of Director’s Interest Notice for Mr Doug Ward.

In addition to the on-market purchase of 235,000 LDX shares on 18 October 2023, this Notice includes the on-market purchase of 5,000 LDX shares on 6 September 2023, and 10,000 LDX shares on 7 September 2023. Lumos Diagnostics (“the Company”) acknowledges the late lodgement of the Appendix 3Y in relation to the latter two transactions.

In relation to the late lodgement of this Appendix 3Y with regards to these latter two transactions, the Company advises the following:

1. The failure to lodge an Appendix 3Y in relation to the on-market purchase of shares by Mr Doug Ward on the 6 September 2023 and on 7 September 2023 was due to an administrative oversight. The Company became aware of this oversight when preparing the Appendix 3Y for the recent on-market purchase of 235,000 shares on the 18 October 2023. As soon as this oversight was identified, the Company included these transactions in the Appendix 3Y that has been lodged on 24 October 2023.
2. The Company and the Directors are aware of their obligations under ASX Listing Rules 3.19A and 3.19B to provide the necessary information to the Company to meet its disclosure requirements. The Company has a Trading Policy in place which sets out Directors’ requirements to notify the Company of changes in interests.
3. The Company considers this late lodgement as an isolated breach. The Company has reviewed its procedures around securities and believes that its current practices are adequate to ensure compliance with the ASX Listing Rules.

Yours sincerely

Tracy Weimar
Company Secretary

This announcement has been authorised by the Board of Directors

-END-

###

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or call +1 941-556-1850.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|---------------------------------------|
| Name of entity | LUMOS DIAGNOSTICS HOLDINGS LTD |
| ABN | 66 630 476 970 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|--------------|
| Name of Director | DOUG WARD |
| Date of last notice | 13 July 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | |
| Date of change | 18 October 2023 |
| No. of securities held prior to change | 1. 225,000 2. 7,500,000 3. 2,995,000 4. 10,100,000 |
| Class | 1. Fully Paid Ordinary Shares 2. Unlisted Options expiring 18 July 2029, ex price \$0.30 3. Unlisted Options expiring 26 August 2027, ex price \$0.0589 4. Unlisted Options expiring 8 May 2028, ex price \$0.0243 |
| Number acquired | 1. 235,000 on 18 October 2023 10,000 on 7 September 2023* 5,000 on 6 September 2023* |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | |
|---|--|
| Number disposed | None |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | 1. 235,000 at \$0.086 or \$20,210 10,000 at \$0.097 or \$970 5,000 at \$0.093 or \$465 |
| No. of securities held after change | 1. 475,000 Fully Paid Ordinary Shares 2. 7,500,000 Unlisted Options expiring 18 July 2029, ex price \$0.30 3. 2,995,000 Unlisted Options expiring 26 August 2027, ex price \$0.0589 4. 10,100,000 Unlisted Options expiring 8 May 2028, ex price \$0.0243 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Acquisition of shares on market |

** Reporting of acquisition of shares on 6 and 7 September 2023 was inadvertently missed at the time due to administrative oversight. These are included here for completeness.*

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | No |

⁺ See chapter 19 for defined terms.